This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (48)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Review  • Hematology/ Hematologic Malignancies  • Anemias  • Alert me on articles by topic  Social Bookmarking   What's this?

Clinical Evolution of a Pleiotropic Cytokine

David H. Henry, MD; Peter Bowers, MD; Michael T. Romano, PhD; Robert Provenzano, MD

Arch Intern Med. 2004;164:262-276.

Recombinant human erythropoietin (epoetin alfa) has been used in clinical settings for more than a decade. Its indications have expanded considerably from its original use as hormone therapy in the treatment of anemia in adults with chronic kidney disease. Since the introduction of epoetin alfa, a greater understanding of anemia pathophysiology and the interactions of erythropoietin, iron, and erythropoiesis has been elucidated. Anemia is now independently associated with increased mortality and disease progression. Potential survival benefits associated with correction of anemia in various patient populations are leading to consideration of earlier, more aggressive treatment of mild to moderate anemia with epoetin alfa. Moreover, this agent's therapeutic use may extend beyond currently accepted roles. Epoetin alfa is undergoing evaluation with promising results in a variety of new clinical settings, including anemia associated with congestive heart failure, ribavirin–interferon alfa treatment of hepatitis C virus infection, and critical illness. Preclinical studies also have established erythropoietin and its recombinant equivalent to be a pleiotropic cytokine with antiapoptotic activity and neuroprotective actions in the central nervous system. The therapeutic potential of epoetin alfa appears yet to be fully realized.

From the Pennsylvania Hospital, Joan Karnell Cancer Center, Philadelphia (Dr Henry); Ortho Biotech Products, LP, Bridgewater, NJ (Dr Bowers); Johnson & Johnson Pharmaceutical Research & Development, Raritan, NJ (Dr Romano); and St John Hospital and Medical Center, Department of Nephrology, Detroit, Mich (Dr Provenzano). Dr Henry is on the speaker's bureau for Ortho Biotech Products, LP. Drs Bowers and Romano are employees of Johnson & Johnson, Inc.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Phase I, Single and Fractionated, Ascending-Dose Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of an Erythropoietin Mimetic Antibody Fusion Protein (CNTO 528) in Healthy Male Subjects
Bouman-Thio et al.
J Clin Pharmacol 2008;48:1197-1207.
ABSTRACT | FULL TEXT  

Protective Effects of Erythropoietin in Cardiac Ischemia: From Bench to Bedside
Lipsic et al.
J Am Coll Cardiol 2006;48:2161-2167.
ABSTRACT | FULL TEXT  

Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models.
LaMontagne et al.
Molecular Cancer Therapeutics 2006;5:347-355.
ABSTRACT | FULL TEXT  

Serum Erythropoietin Levels and Infarct Size
Lipsic et al.
J Am Coll Cardiol 2006;47:468-469.
FULL TEXT  

Erythropoietin Increases Asymmetric Dimethylarginine in Endothelial Cells: Role of Dimethylarginine Dimethylaminohydrolase
Scalera et al.
J. Am. Soc. Nephrol. 2005;16:892-898.
ABSTRACT | FULL TEXT  

New Avenues of Exploration for Erythropoietin
Maiese et al.
JAMA 2005;293:90-95.
ABSTRACT | FULL TEXT